Drug · CHEMBL154

NAPROXEN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. NAPROXEN. Drugs and targets, record CHEMBL154. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL154

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: NAPROXEN; ChEMBL
ChEMBL ID: CHEMBL154; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Arthrosin 250, Arthrosin 250 ec, Arthrosin 500, Arthrosin 500 ec, Condrotec, Ec-naprosyn, Feminax ultra, Grenoxal, Kenosyn, Laraflex, Napratec op, Naprosyn, Naprosyn 375, Naprosyn ec, Naproxen component of vimovo, Nycopren, Pranoxen continus, Prosaid, Rheuflex 250, Rheuflex 500, Rimoxyn, Stirlescent, Timpron, Timpron 250 ec, Timpron 500 ec, Valrox; ChEMBL
Other names: NAPROXEN COMPONENT OF PN400, NSC-750183, NSC-757239, Naproxene, Naproxeno, RS-3540; ChEMBL
Other form: NAPROXEN SODIUM, CHEMBL1200806; Drugs and targets
DrugBank: DB00788; DrugBank
InChIKey: CMWTZPSULFXXJA-VIFPVBQESA-N; ChEMBL
Open Targets' highest stage: Approval, for 23 of its 63 diseases, from ATC, DailyMed and TTD; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
PTGS1	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5742
PTGS2	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5743

Source ChEMBL

Diseases63

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
osteoarthritis	Approval	DailyMed and TTD	166	23	https://conductscience.org/library/drugs?q=MONDO_0005178
Pain	Approval	DailyMed	27	9	https://conductscience.org/library/drugs?q=HP_0012531
Low back pain	Phase 2/3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=HP_0003419
osteoarthritis, knee	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0005416
migraine disorder	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0005277
juvenile idiopathic arthritis	Approval	DailyMed	123	5	https://conductscience.org/library/drugs?q=MONDO_0011429
Dysmenorrhea	Approval	DailyMed	14	5	https://conductscience.org/library/drugs?q=HP_0100607
rheumatoid arthritis	Approval	DailyMed	146	4	https://conductscience.org/library/drugs?q=MONDO_0008383
ankylosing spondylitis	Approval	DailyMed	6	4	https://conductscience.org/library/drugs?q=MONDO_0005306
Back pain	Approval	DailyMed	5	3	https://conductscience.org/library/drugs?q=HP_0003418

1 to 10 of 63Source Open Targets

See all 63 diseases

Trials184

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 85 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00346216	Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen	Phase 4	24,081	2017-05-01	naproxen	Its name	ClinicalTrials.gov
NCT03472469	MAST Trial: Multi-modal Analgesic Strategies in Trauma	Phase 4	1,561	2021-06-10	naproxen	Its name	ClinicalTrials.gov
NCT00876187	A Study of Tanezumab in Adults With Chronic Low Back Pain	Phase 2	1,359	2021-07-07	naproxen	Its name	ClinicalTrials.gov
NCT01208207	A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)	Phase 3	1,015	2015-07-02	naproxen	Its name	ClinicalTrials.gov
NCT00830063	Tanezumab In Osteoarthritis Of The Knee (2)	Phase 3	832	2021-05-13	naproxen	Its name	ClinicalTrials.gov
NCT00387881	TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)	Phase 3	679	2009-07-10	naproxen	Its name	ClinicalTrials.gov
NCT00664560	Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis	Phase 3	614	2012-02-27	naproxen	Its name	ClinicalTrials.gov
NCT00665431	Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis	Phase 3	610	2011-12-06	naproxen	Its name	ClinicalTrials.gov
NCT01712009	NOLAN: Naproxen or Loratadine and Neulasta	Phase 2	600	2016-03-09	naproxen	Its name	ClinicalTrials.gov
NCT00602420	Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)	Phase 3	510	2015-05-12	naproxen	Its name	ClinicalTrials.gov

1 to 10 of 184

See all 184 trials

Comparisons in its trials63

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: Number of Participants Discharged From the Hospital With an Opioid Prescription	527 of 787	476 of 774	1,561	NCT03472469	Trial comparisons
Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: deaths from any cause	29 of 787	36 of 774	1,561	NCT03472469	Trial comparisons
Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: serious adverse events	29 of 787	36 of 774	1,561	NCT03472469	Trial comparisons
Naproxen vs Placebo: serious adverse events	5 of 257	3 of 253	510	NCT00602420	Trial comparisons
Sumatriptan/Naproxen vs Placebo: serious adverse events	0 of 254	0 of 246	500	NCT00387881	Trial comparisons
Sumatriptan/Naproxen vs Placebo: Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment	61 of 222	101 of 221	443	NCT00387881	Trial comparisons
Sumatriptan/Naproxen vs Placebo: Sustained Headache Relief 2-24 Hours After Treatment	110 of 222	77 of 221	443	NCT00387881	Trial comparisons
PN400 (VIMOVO) vs Naproxen: The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events or to Duodenal Ulcer	7 of 218	26 of 216	434	NCT00527787	Trial comparisons
PN400 (VIMOVO) vs Naproxen: The Number of Participants With Pre-Specified NSAID-Associated Upper GI Adverse Events or Duodenal Ulcers	114 of 218	149 of 216	434	NCT00527787	Trial comparisons
PN400 (VIMOVO) vs Naproxen: Heartburn Symptom Resolution, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit	140 of 218	65 of 216	434	NCT00527787	Trial comparisons

1 to 10 of 63

See all 63 comparisons in its trials

Papers from its trials75

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39260540	RESULT	1	PubMed
33486130	RESULT	1	PubMed
30233140	RESULT	1	PubMed
27737664	RESULT	1	PubMed
27382251	RESULT	1	PubMed
27121942	RESULT	1	PubMed
26926930	RESULT	1	PubMed
25989985	RESULT	1	PubMed
25579873	RESULT	1	PubMed
24108307	RESULT	1	PubMed

1 to 10 of 75

See all 75 papers from its trials

Tests in its trials2

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Treatment Risk Task	1	0	ConductCognition
Verbal Learning	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL154

GET https://conductscience.org/api/drugs/v1/CHEMBL154/diseases?page=2

API reference For AI assistants